Literature DB >> 31544925

Nurse-led vs. usual-care for atrial fibrillation.

E P J Petra Wijtvliet1,2, Robert G Tieleman2, Isabelle C van Gelder3, Nikki A H A Pluymaekers1, Michiel Rienstra3, Richard J Folkeringa4, Patrick Bronzwaer5, Arif Elvan6, Jan Elders7, Raymond Tukkie8, Justin G L M Luermans1, A D I Thea Van Asselt9, Sander M J Van Kuijk10, Jan G Tijssen11, Harry J G M Crijns1.   

Abstract

BACKGROUND: Nurse-led integrated care is expected to improve outcome of patients with atrial fibrillation compared with usual-care provided by a medical specialist. METHODS AND
RESULTS: We randomized 1375 patients with atrial fibrillation (64 ± 10 years, 44% women, 57% had CHA2DS2-VASc ≥ 2) to receive nurse-led care or usual-care. Nurse-led care was provided by specialized nurses using a decision-support tool, in consultation with the cardiologist. The primary endpoint was a composite of cardiovascular death and cardiovascular hospital admissions. Of 671 nurse-led care patients, 543 (81%) received anticoagulation in full accordance with the guidelines against 559 of 683 (82%) usual-care patients. The cumulative adherence to guidelines-based recommendations was 61% under nurse-led care and 26% under usual-care. Over 37 months of follow-up, the primary endpoint occurred in 164 of 671 patients (9.7% per year) under nurse-led care and in 192 of 683 patients (11.6% per year) under usual-care [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.69 to 1.04, P = 0.12]. There were 124 vs. 161 hospitalizations for arrhythmia events (7.0% and 9.4% per year), and 14 vs. 22 for heart failure (0.7% and 1.1% per year), respectively. Results were not consistent in a pre-specified subgroup analysis by centre experience, with a HR of 0.52 (95% CI 0.37-to 0.71) in four experienced centres and of 1.24 (95% CI 0.94-1.63) in four less experienced centres (P for interaction <0.001).
CONCLUSION: Our trial failed to show that nurse-led care was superior to usual-care. The data suggest that nurse-led care by an experienced team could be clinically beneficial (ClinicalTrials.gov NCT01740037). TRIAL REGISTRATION NUMBER: ClinicalTrials.gov (NCT01740037).
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.

Entities:  

Keywords:  Usual-care; Atrial fibrillation; Cardiovascular mortality and morbidity; Heart failure; Nurse-led care; Randomized clinical trial; Stroke

Mesh:

Substances:

Year:  2020        PMID: 31544925     DOI: 10.1093/eurheartj/ehz666

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  13 in total

1.  Rhythm Control Vs Rate Control in a Contemporary Ambulatory Atrial Fibrillation Cohort: Post Hoc Analysis of the IMPACT-AF Trial.

Authors:  Arun Govindapillai; Jafna L Cox; Lehana Thabane; Steve Doucette; Feng Xie; James H MacKillop; Antonio Ciaccia; Shurjeel H Choudhri; Joanna M Nemis-White; Laura M Hamilton; Ratika Parkash
Journal:  CJC Open       Date:  2022-03-08

2.  Integrated Care in Atrial Fibrillation: A Road Map to the Future.

Authors:  Aditya Bhat; Shaun Khanna; Henry H L Chen; Arnav Gupta; Gary C H Gan; A Robert Denniss; C Raina MacIntyre; Timothy C Tan
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2021-03-05

3.  Care and referral patterns in a large, dedicated nurse-led atrial fibrillation outpatient clinic.

Authors:  F R Piersma; J Neefs; W R Berger; N W E van den Berg; R Wesselink; S P J Krul; J R de Groot
Journal:  Neth Heart J       Date:  2021-12-17       Impact factor: 2.854

4.  Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort.

Authors:  Yutao Guo; Jun Guo; Xiangmin Shi; Yuan Yao; Yihong Sun; Yunlong Xia; Bo Yu; Tong Liu; Yundai Chen; Gregory Y H Lip
Journal:  Eur J Intern Med       Date:  2020-10-13       Impact factor: 4.487

5.  Incidence and outcome of atrial fibrillation: diversity throughout Europe.

Authors:  Michiel Rienstra; Isabelle C Van Gelder
Journal:  Eur Heart J       Date:  2021-02-21       Impact factor: 29.983

6.  Rate control drugs differ in the prevention of progression of atrial fibrillation.

Authors:  Tim Koldenhof; Petra E P J Wijtvliet; Nikki A H A Pluymaekers; Michiel Rienstra; Richard J Folkeringa; Patrick Bronzwaer; Arif Elvan; Jan Elders; Raymond Tukkie; Justin G L M Luermans; Sander M J van Kuijk; Jan G P Tijssen; Isabelle C van Gelder; Harry J G M Crijns; Robert G Tieleman
Journal:  Europace       Date:  2022-03-02       Impact factor: 5.214

7.  Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation.

Authors:  José Maria Farinha; Ian D Jones; Gregory Y H Lip
Journal:  Eur Heart J Suppl       Date:  2022-02-14       Impact factor: 1.803

8.  Integrated management of atrial fibrillation in primary care: results of the ALL-IN cluster randomized trial.

Authors:  Carline J van den Dries; Sander van Doorn; Frans H Rutten; Ruud Oudega; Sjef J C M van de Leur; Arif Elvan; Lisa Oude Grave; Henk J G Bilo; Karel G M Moons; Arno W Hoes; Geert-Jan Geersing
Journal:  Eur Heart J       Date:  2020-08-07       Impact factor: 29.983

Review 9.  Computational models of atrial fibrillation: achievements, challenges, and perspectives for improving clinical care.

Authors:  Jordi Heijman; Henry Sutanto; Harry J G M Crijns; Stanley Nattel; Natalia A Trayanova
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 10.787

10.  Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report.

Authors:  Emelia J Benjamin; Sana M Al-Khatib; Patrice Desvigne-Nickens; Alvaro Alonso; Luc Djoussé; Daniel E Forman; Anne M Gillis; Jeroen M L Hendriks; Mellanie True Hills; Paulus Kirchhof; Mark S Link; Gregory M Marcus; Reena Mehra; Katherine T Murray; Ratika Parkash; Ileana L Piña; Susan Redline; Michiel Rienstra; Prashanthan Sanders; Virend K Somers; David R Van Wagoner; Paul J Wang; Lawton S Cooper; Alan S Go
Journal:  J Am Heart Assoc       Date:  2021-08-05       Impact factor: 6.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.